On Monday, Entergy Corporation (NYSE:ETR)’s shares inclined 1.72% to $70.40.
Entergy Corporation (ETR) declared that Robert Hall III has been named vice president, federal governmental affairs. Based in Entergy’s Washington, D.C., office, Hall’s responsibilities comprise developing and implementing the company’s stakeholder engagement strategies with elected officials and key policymakers.
Hall comes to Entergy from General Electric, where he served as the lead U.S. government affairs advocate for the company’s multiple energy technologies through his role as executive counsel. During his nearly 30 year career in Washington, Hall also worked at Dutko Worldwide as a senior vice president, as managing director of global government affairs at INVISTA and at Koch Industries as director, government affairs. He began his career as legislative counsel in the office of Sen. Sam Nunn.
Hall received his bachelor’s degree in political science from the University of Georgia and his Juris Doctor from the University of Georgia School of Law. He is a member of the State Bar of Georgia. Hall will report to Kimberly Despeaux, senior vice president, federal policy, regulatory and governmental affairs.
Entergy Corporation, together with its auxiliaries, engages in the electric power production and retail electric distribution operations in the United States. It operates in two segments, Utility and Entergy Wholesale Commodities. The Utility segment generates, transmits, distributes, and sells electric power in portions of Arkansas, Mississippi, Texas, and Louisiana, counting the City of New Orleans; and distributes natural gas.
Pacira Pharmaceuticals Inc (NASDAQ:PCRX)’s shares dropped -4.51% to $59.50.
Pacira Pharmaceuticals, Inc. (PCRX) declared that Aratana Therapeutics, Inc. (PETX) shared positive results from its pivotal field effectiveness study of AT-003, the company’s bupivacaine liposome injectable suspension licensed from Pacira, for managing postsurgical pain in dogs.
The randomized, blinded, multicenter pivotal study in dogs undergoing knee surgery demonstrated statistically noteworthy improvements in pain evaluation contrast to placebo at each of the 24-hour intervals up to 72 hours following surgery (P<0.05). Based on current timelines for the FDA approval process, Aratana anticipates startning commercialization of AT-003 in dogs in 2016.
acira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
At the end of Monday’s trade, Pacira Pharmaceuticals Inc (NASDAQ:PCRX)‘s shares surged 4.07% to $12.02.
POZEN Inc. (POZN) a pharmaceutical company committed to developing medicine that transforms lives, recently declared the acquisition of Tribute Pharmaceuticals Canada Inc. (TBUFF), a Canadian specialty pharmaceutical company, in a transaction valued at about US$146 million. Upon completion of the acquisition, which is predictable to occur in the fourth quarter of 2015, the combined company will be named Aralez Pharmaceuticals plc (“Aralez” or the “Company”) and domiciled in Ireland. Upon closing, Aralez is predictable to trade on NASDAQ and TSX.
The acquisition will create a premier specialty pharmaceutical company with a broad portfolio of commercial products and a growth plan focused on innovative products and acquisitions and the commercialization of portfolio products in the United States and Canada. The Company will also be well positioned to expand its foreign presence through potential international sales and licensing, manufacturing and product development.
Recently, POZEN’s lead proprietary product is YOSPRALA™, a coordinated-delivery tablet designed to provide the cardiovascular benefit of aspirin while reducing its gastrointestinal side effects. POZEN also has two commercial pain products, VIMOVO® and Treximet®, which are marketed by partners worldwide. Tribute’s highly complementary portfolio comprises Fibricor®, Bezalip® SR and Visken®/Viskazide® for various cardiovascular indications; Cambia® and Fiorinal® and Fiorinal® C for acute migraines and tension headaches, respectively; and a range of other specialty products. Tribute also is pursuing active and ongoing business development activities.
POZEN Inc., a pharmaceutical company, develops products for the treatment of acute and chronic pain, and pain related conditions in the United States and internationally. Its principal PA product candidates comprise PA32540 and PA8140 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, which have accomplished clinical development in the United States.
Ingram Micro Inc. (NYSE:IM), ended its Monday’s trading session with -0.04% loss, and closed at $24.07.
Ingram Micro Inc. ( IM) anticipates to release financial results for the second quarter ending July 4, 2015, after the market closes on Thursday, July 30, 2015. A conference call with executive administration will be held at 5 p.m. ET (2 p.m. PT) on that day.
Ingram Micro Inc. distributes information technology (IT) products; and provides supply chain and mobile device lifecycle services worldwide. The company offers printers, scanners, displays, projectors, monitors, panels, mass storage, and tape products; digital signage products; digital cameras and video disc players, game consoles, televisions, audio, small appliances, media administration, and home control products; barcode/card printers, AIDC scanners and software, and wireless infrastructure products; Internet protocol video surveillance, security and fire alarm systems, and access control smart cards; processors, motherboards, hard drives, and memory products; and ink and toner supplies, paper, carrying cases, and anti-glare screens.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
